EXJADE Drug Patent Profile

When do Exjade patents expire, and when can generic versions of Exjade launch?

Exjade is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in EXJADE is deferasirox. There are twenty drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the deferasirox profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Exjade

A generic version of EXJADE was approved as deferasirox by ACTAVIS ELIZABETH on January 26^th, 2016.

Summary for EXJADE

US Patents:	0
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for EXJADE

Paragraph IV (Patent) Challenges for EXJADE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
EXJADE	Tablets for Suspension	deferasirox	125 mg, 250 mg, and 500 mg	021882	1	2011-10-28

US Patents and Regulatory Information for EXJADE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	EXJADE	deferasirox	TABLET, FOR SUSPENSION;ORAL	021882-001	Nov 2, 2005	AB	RX	Yes	No
Novartis	EXJADE	deferasirox	TABLET, FOR SUSPENSION;ORAL	021882-002	Nov 2, 2005	AB	RX	Yes	No
Novartis	EXJADE	deferasirox	TABLET, FOR SUSPENSION;ORAL	021882-003	Nov 2, 2005	AB	RX	Yes	Yes

International Patents for EXJADE

See the table below for patents covering EXJADE around the world.

Country	Patent Number	Title	Estimated Expiration
Slovakia	284319
Australia	718037
Poland	194758
Norway	2006017
South Korea	20050098029
Germany	69716602

Supplementary Protection Certificates for EXJADE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0914118	C00914118/01	Switzerland		PRODUCT NAME: DEFERASIROX; REGISTRATION NUMBER/DATE: SWISSMEDIC 57466 03.11.2005
0914118	SPC 035/2006	Ireland		SPC 035/2006: 20070528, EXPIRES: 20210827
0914118	290	Finland
0914118	PA2007001	Lithuania		PRODUCT NAME: DEFERASIROXUM; REGISTRATION NO/DATE: EU/1/06/356/001 2006 08 28, EU/1/06/356/002 2006 08 28, EU/1/06/356/003 2006 08 28, EU/1/06/356/004 2006 08 28, EU/1/06/356/005 2006 08 28, EU/1/06/356/00 20060828
0914118	CA 2006 00035	Denmark
0914118	PA2007001,C0914118	Lithuania		PRODUCT NAME: DEFERASIROXUM; REGISTRATION NO/DATE: EU/1/06/356/001 2006-08-28, EU/1/06/356/002 2006-08-28, EU/1/06/356/003 2006-08-28, EU/1/06/356/004 2006-08-28, EU/1/06/356/005 2006-08-28, EU/1/06/356/00 20060828

Last updated: February 3, 2026

What is the market and therapeutic profile of EXJADE?

EXJADE (deferasirox) is an oral iron chelator developed by Novartis for managing chronic iron overload. Approved in multiple jurisdictions, it targets patients with transfusional iron overload from conditions such as thalassemia major, sickle cell disease, and myelodysplastic syndromes.

The global iron chelation therapy market is projected to reach $2.1 billion by 2027, growing at 5.8% CAGR (CAGR = compound annual growth rate) from 2020, driven by the rising prevalence of transfusion-dependent anemias.

How does EXJADE’s regulatory and patent status influence its market potential?

Regulatory approvals extend across the U.S., Europe, Japan, and other key markets, with initial FDA approval in 2005. Regulatory agencies have granted Orphan Drug Designation, providing incentives such as market exclusivity—up to 7 years in the U.S., 10 in the EU.

Patent landscape: The primary patent covering deferasirox expired in 2019 in some jurisdictions but remains under patent protection in key markets until 2025–2028. Patent expiry risks open generic competition, impacting revenues.

What are the sales and revenue trends for EXJADE?

Historical sales data (up to 2022):

Year	Global Revenue (USD millions)	Notes
2019	850	Peak, driven by mature markets
2020	885	Slight growth, COVID-19 impact felt
2021	820	Slight decline, patent expiration concerns
2022	790	Stabilization, generic entry pressures

Sales are primarily from North America (40%), Europe (35%), and Asia-Pacific (15%). The remainder derived from emerging markets with growing demand.

Revenue drivers: Patient population growth, increased off-label use, and improved adherence due to better formulations. Competition from deferiprone and deferoxamine also affects market share.

How do competitors and pipeline developments affect EXJADE’s prospects?

Main competitors:

• Deferiprone (Ferriprox): Oral, approved in the U.S. since 2011; has a distinct safety profile.
• Deferoxamine (Desferal): Injectable, generally reserved for severe cases; older but effective.

Pipeline: Novartis is developing next-generation chelators (e.g., novartis’ JL-553) aimed at improved safety and dosing profiles. These developments could erode EXJADE’s market share if successful.

What are the key pharmacological and safety considerations?

Efficacy: EXJADE effectively reduces serum ferritin levels and liver iron content over 24 weeks. Dose adjustments are critical to avoid toxicity.

Safety profile: Common adverse events include gastrointestinal disturbances, increased creatinine, and rash. Rare but serious issues include renal failure and hepatic dysfunction. Long-term safety data is continuously monitored.

What are the patent and regulatory challenges?

Patent expiries threaten exclusivity, especially in generics-prone markets. Regulatory agency requirements necessitate ongoing post-market surveillance, which might delay approvals of future formulations or equivalent generics.

What is the investment outlook?

Strengths:

• Established brand with global presence.
• Growing patient population and ongoing demand for iron chelation.
• Market incentives like orphan drug status.

Weaknesses:

• Patent expiration risks.
• Competition from newer chelators.
• Potential generic entry could reduce prices and profits.

Opportunities:

• Expansion into developing markets.
• Launch of next-generation formulations.
• Growing prevalence of transfusional iron overload due to aging populations and improved survival rates.

Threats:

• Patent cliffs.
• Competition from biosimilars or innovative therapies.
• Regulatory hurdles delaying new formulations.

Key Takeaways

• EXJADE is a mature, globally approved iron chelator with consistent sales but approaching patent expiration.
• The market faces pressure from generics, with sales largely driven by existing patient populations.
• Pipeline and pipeline competitors represent significant risks and opportunities.
• Safety profile management and regulatory compliance remain critical to sustaining market presence.

FAQs

1. What is the primary therapeutic indication for EXJADE?
Chronic iron overload in transfusion-dependent patients, primarily those with thalassemia major and sickle cell disease.

2. How does patent expiry impact EXJADE’s market share?
Patent expiry opens pathways for generic competitors, potentially decreasing pricing power and sales volumes.

3. What are the main safety concerns associated with EXJADE?
Renal and hepatic toxicity are notable risks, requiring diligent monitoring and dose adjustments.

4. Are there any new formulations of deferasirox in development?
Yes, Novartis and other companies are working on formulations aimed at improving safety and compliance.

5. How does the pipeline influence EXJADE’s future growth?
Pipeline products could either expand the market or erode EXJADE’s share, depending on their success and approval timelines.

---

Sources

[1] MarketWatch, “Iron Chelation Therapy Market Size, Share & Trends Analysis Report,” 2022.
[2] Novartis Annual Reports, 2019–2022.
[3] U.S. FDA, “Approved Drugs Database,” 2022.
[4] European Medicines Agency, “Orphan Designations and Approvals,” 2022.